Evidence map›Paper›PMID 33659978›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2021

Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function.

Rodolfo J Galindo, Francisco J Pasquel, Priyathama Vellanki, Cesar Zambrano, Bonnie Albury, Citlalli Perez-Guzman, Zheng Ziduo, Guillermo E Umpierrez

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rodolfo J GalindoDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.ORCID 0000-0002-9295-3225
Francisco J PasquelDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Priyathama VellankiDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Cesar ZambranoDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Bonnie AlburyDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Citlalli Perez-GuzmanDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Zheng ZiduoRollins School of Public Health, Emory University, Atlanta, GA 30322, USA.
Guillermo E UmpierrezDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30303, USA.
Emory University · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Emory University BIRCWH ProgramK12HD085850 · NICHD · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, STERK, CLAIRE E · 2015 to 2023
$4.4M
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsK23GM128221 · NIGMS · EMORY UNIVERSITY · PI PASQUEL, FRANCISCO J · 2018 to 2022
$957k
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
NCATS NIH HHS UL1 TR002378NICHD NIH HHS K12 HD085850NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK111024NIGMS NIH HHS K23 GM128221
6 · The paper itself

Abstract

introductionDifferences in biochemical parameters of diabetic ketoacidosis in patients with end-stage kidney disease (ESKD) has not been established. Accordingly, we assessed the relationship between degree of metabolic acidosis and ß-hydroxybutyrate in patients with ESKD (eGFR < 15 mL/min/1.73 m2), moderate renal failure (eGFR 15-60), or preserved renal function (eGFR > 60).

methodsThis observational study included adults (18-80 years) with diabetes ketoacidosis (DKA), admitted to Emory University Hospitals between January 1, 2006 to December 31, 2016. DKA and renal stages were confirmed on admission laboratory values.

resultsAdmission bicarbonate levels (13.9 ± 5 vs 13.4 ± 5.3 vs 13.8 ± 4.2 mmol/L, P = 0.7), and pH levels (7.2 ± 0.3 vs 7.2 ± 0.2 vs 7.2 ± 0.2, P = 0.8) were similar among groups. Patients with ESKD had lower mean ß-hydroxybutyrate level (4.3 ± 3.3 vs 5.6 ± 2.9 vs 5.9 ± 2.5 mmol/L, P = 0.01), but higher admission glucose (852 ± 340.4 vs 714.6 ± 253.3 mg/dL vs 518 ± 185.7 mg/dL, P < 0.01), anion gap (23.4 ± 7.6 vs 23 ± 6.9 vs 19.5 ± 4.7 mmol/L, P < 0.01), and osmolality (306 ± 20.6 vs 303.5 ± vs 293.1 ± 3.1mOsm/kg, P < 0.01) compared with patients with moderate renal failure and preserved renal function, respectively. The sensitivity of ß-hydroxybutyrate > 3 mmol/L for diagnosing DKA by bicarbonate level < 15 and <18 mmol/L was 86.9% and 72% in ESKD, 89.3% and 83.7% in moderate renal failure, and 96.2% and 88.3% in preserved renal function. In patients with ESKD, the corresponding ß-hydroxybutyrate with bicarbonate levels < 10, 10-15, <18 mmol/L were 5.5, 3.9, 3.0 mmol/L, respectively.

conclusionsSignificant metabolic differences were found among DKA patients with different levels of renal function. In patients with ESKD, a ß-hydroxybutyrate level > 3 mmol/L may assist with confirmation of DKA diagnosis.

Indexed as

3-Hydroxybutyric AcidAcid-Base EquilibriumAdolescentAdultAgedAged, 80 and overBicarbonatesBlood GlucoseDiabetic KetoacidosisFemaleGlomerular Filtration RateHumansHydrogen-Ion ConcentrationKidneyKidney Failure, ChronicKidney Function Tests3-Hydroxybutyric AcidBicarbonatesBlood Glucosechronic kidney diseasediabetes ketoacidosisdiagnosisend-stage kidney diseasehyperglycemic crises

Identifiers

PMID33659978
PMCPMC8502445
OpenAlexW3135813241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.